Vivek Ramaswamy Is a Fraud—and Always Has Been | Opinion
https://www.newsweek.com/vivek-ramaswamy-fraud-always-has-been-opinion-1823853
"Vivek Ramaswamy's artful narrative, meticulously tailored for the GOP primary voter, weaves a tale of principled sacrifice and success. According to his version, he helmed the leadership of Roivant, a multi-billion-dollar American pharmaceutical company he founded, and gallantly relinquished his CEO role in 2021 due to his unwavering stance against ESG principles, despite facing opposition from his liberal workforce. While this narrative might seem appealing, it is akin to the endless "flip-flops" that have plagued his campaign—an elaborate work of fiction that unravels upon a modicum of scrutiny.
Let's start with the basics. Ramaswamy has funded his campaign through the sale of over $32 million in Roivant stock options in February of this year. This could lead one to believe that Roivant, based in Bermuda, is thriving and that Ramaswamy is a great entrepreneur. Except the company reported staggering losses of $1.2 billion in its financial report of March 2023. This isn't a one-time slump: In March 2022, when Ramaswamy was still Roivant's chairman and a major shareholder, the company reported an annual loss of $924.1 million.
Ramaswamy's defenders may argue that Roivant performed better during his tenure as CEO in 2021, but alas, the numbers tell a different story. The reality is that Roivant's finances were abysmal under Ramaswamy's watch. During his tenure in 2019, the company's net operating loss exceeded $530 million. By 2020, the losses had doubled to over $1 billion, accompanied by a 65 percent decline in revenue.
These numbers raise a puzzling question: How can a company consistently bleeding billions trade at over $10 a share?
The answer might lie in Ramaswamy's implementation of Roivant's diversity, equity, and inclusion (DEI) initiative, called Roivant Social Ventures, during his CEO tenure. Launched in 2020 while Ramaswamy was still CEO, this initiative aimed to foster "DEI opportunities for future leaders in biopharma and biotech."
While Ramaswamy vocally opposes ESG principles, Roivant's major institutional investors—including Morgan Stanley, Viking Global, and BlackRock, the very firms he criticizes by name—are among its largest stakeholders, owning over 500 million shares. Ramaswamy himself holds more than 80 million shares, making him an essential partner of these major ESG funds.
In a deeply ironic twist, Ramaswamy's anti-"woke" campaign is being bankrolled by the profits reaped from the very policies he denounces."